Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (SPICI)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05219318 |
|
Recruitment Status :
Recruiting
First Posted : February 2, 2022
Last Update Posted : March 13, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this study is to demonstrate the non-inferiority of treatment pause versus treatment continuation in good or intermediate risk with only one adverse prognostic factor as per IMDC mRCC patients with a confirmed objective response at 12 months of treatment with PD-1/PD-L1 ICI plus VEGFR-TKI.
Tolerance and quality of life of treatment pause with PD-1/PD-L1 ICI + VEGFR-TKI compared to treatment continuation will be reported. In France, its impact on healthcare resource utilization will also be assessed.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Metastatic Renal Cell Carcinoma Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score | Drug: Combination PD-1/PD-L1 ICI + VEGFR-TKI Other: Treatment pause | Phase 3 |
Although multiple combinations therapies in particular PD-1/PD-L1 immune-checkpoint inhibitors (PD-1/PD-L1 ICIs) in combination with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) are approved and have improved patient's outcomes with mRCC, they are maintained until disease progression and treatment pause after an objective response has not been fully explored [5-7]. The good-risk population is characterised by prolonged survival therefore a treatment pause in this population could impact the quality of life, safety and total cost of care, without impacting outcome. As well, intermediate risk population group is heterogeneous, while the one's with only one adverse prognostic factor seems to be closed to the outcome of good risk population [11-15]. As the purpose of the study is to target patients with an objective response, there is already a selection of patients with a better outcome.
Patient will be randomised after 12 months of treatment with PD-1/PD-L1 ICI plus VEGFR-TKI (treatment pause versus treatment continuation) and follow every 3 months for a period of 12 months following by 12 additional months for survival follow-up.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 372 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | SPICI: Strategic Treatment Pause of First-line Immune Check Point Inhibitor + VEGFR-Tyrosine Kinase Inhibitor in Good or Only One Adverse Prognostic Factor in Intermediate Risk Metastatic Renal Cell Carcinoma (mRCC) With an Objective Response: a Randomised, Non-inferiority Phase III Study |
| Actual Study Start Date : | January 23, 2023 |
| Estimated Primary Completion Date : | January 2024 |
| Estimated Study Completion Date : | January 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Treatment pause
Treatment pause for 12 months
|
Other: Treatment pause
Combination regimens discontinuation until progression with the possibility to resume initial combination regimens at progression |
|
Active Comparator: Treatment continuation
Treatment continuation regimens with PD-1/PD-L1 ICI + VEGFR-TKI until disease progression or unacceptable toxicity
|
Drug: Combination PD-1/PD-L1 ICI + VEGFR-TKI
The study will enroll patients achieving an objective response after 12 months of treatment with the combination PD-1/PD-L1 ICI + VEGFR-TKI as recommended in the Summary of Product Characteristics (SmPC) |
- Proportion of participants without progression [ Time Frame: Up to 12 months after randomisation ]Disease progression at up to 12 months after randomisation will be based on a blinded independent central review (BICR) according to RECIST v1.1 criteria, with tumor assessment performed every 12 weeks during study participation
- Overall safety profile and tolerability event [ Time Frame: Up to 12 months after randomisation ]Proportion of participants who experience an adverse event or serious adverse event and mean number of adverse events or serious adverse events up to 12 months after randomisation
- Overall survival (OS) [ Time Frame: From randomisation until 2 years of follow-up ]OS is defined as the time between the date of randomisation and the date of death due to any cause
- Progression-free survival (PFS) [ Time Frame: From randomisation until 2 years of follow-up ]PFS is defined as the time between date of randomisation and the first date of the documented disease progression, or death due to any cause, whichever occurs first
- Mean change in quality of life [ Time Frame: Up to 12 months after randomisation ]Measured by the NCCN functional assessment of cancer therapy-kidney symptom index (FKSI-19). The NCCN FKSI-19 is a 19-item scale that measures tumor specific health-related quality of life in kidney cancer participants. A higher score indicates fewer symptoms
- Quality-adjusted survival [ Time Frame: Up to 12 months after randomisation ]The quality-adjusted time without symptoms or toxicity (Q-TWiST) is a simultaneous assessment of time without toxicity or disease progression, which essentially examines the trade-off between AEs and treatment benefits
- Anxiety and depression [ Time Frame: Up to 12 months after randomisation ]Mean scores in the Hospital Anxiety and Depression Scale at up to 12 months after randomisation
- Site and distribution of the sites of progression: known lesions, new lesion(s) or both [ Time Frame: From randomisation until 2 years of follow-up ]
- Distribution of treatment modality after progression [ Time Frame: From randomisation until 2 years of follow-up ]Proportion of participants treated after progression with surveillance, focal treatment or general treatment
- Percentage of patients with status SD or in objective response at 6 months after restarting PD-1/PD-L1 ICI + VEGFR-TKI [ Time Frame: From randomisation until 2 years of follow-up ]
- Healthcare resource utilisation [ Time Frame: Up to 12 months after randomisation ]Costs of care will be estimated in the perspective of the French Healthcare System over a 12-month times horizon. Conventional tariffs of hospitalizations will be used to calculate costs
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years at time of signing informed consent form
- Signed informed consent form
- Histological confirmation of RCC with a Clear-cell component, including subject who also have a sarcomatoïd feature
- Advanced (not amenable to curative surgery or radiation therapy) or Metastatic RCC (American Joint Committee on Cancer [AJCC] Stage IV)
- Participants with good or intermediate risk with only one adverse prognostic factor will be eligible as per International Metastatic RCC Database Consortium (IMDC) criteria
- Prior first line therapy for mRCC with the combination of PD-1/ PD-L1 ICI plus VEGFR-TKI
- First line treatment with the combination of PD-1/PD-L1 ICI and VEGFR-TKI must be ongoing whatever the dose with no period of discontinuation > 6 consecutive weeks in the last 12 months for the PD-1/PD-L1 ICI, and 2 consecutive weeks in the last 3 months before randomisation for the VEGFR-TKI
- Patients with an objective response (complete response or partial response) after 12 months of the combination treatment with PD-1/PD-L1 ICI and VEGFR-TKI. CT scan at the initiation of this treatment must be available.
- Karnofsky Performance Status (KPS) grade ≥ 70%
- Measurable disease as per RECIST v1.1 per investigator
- Adequate organ function
- Females of childbearing potential must use a highly effective contraception (combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral ; intravaginal ;transdermal) ; progestogen-only hormonal contraception associated with inhibition of ovulation (oral ; injectable ; implantable ; intrauterine device (IUD) ; intrauterine hormone-releasing system ( IUS)) ; bilateral tubal occlusion ; vasectomised partner ; sexual abstinence) and continue its use for 5 months after the last PD1/PD L1 ICI administration.
- Sexually active male patients must agree to use condoms and continue its use for 5 months after the last PD1/PD L1 ICI administration.
- Willingness and ability to comply with study procedures.
- Patient affiliated to a social security system or benefit from the same system
Exclusion Criteria:
- Any active central nervous system (CNS) metastases
- Prior therapy with PD-1/PD-L1 ICI or VEGFR-TKI monotherapy.
- Poorly controlled hypertension despite antihypertensive therapy
- More than one adverse prognostic factor (IMDC criteria)
- Women who are pregnant or lactating;
- Current participation in an investigational program
- Patient with any medical or psychiatric condition or disease, which would make the patient inappropriate for entry into this study
- Adults who are the subject of legal protection measures
- Persons deprived of their liberty by a judicial or administrative decision
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05219318
| Contact: Marine GROSS-GOUPIL, MD PhD | (0)5 56 79 58 08 ext +33 | marine.gross-goupil@chu-bordeaux.fr | |
| Contact: Alain RAVAUD, PU-PH | alain.ravaud@chu-bordeaux.fr |
Show 27 study locations
| Principal Investigator: | Marine GROSS-GOUPIL, MD PhD | University Hospital, Bordeaux |
| Responsible Party: | University Hospital, Bordeaux |
| ClinicalTrials.gov Identifier: | NCT05219318 |
| Other Study ID Numbers: |
CHUBX 2021/08 |
| First Posted: | February 2, 2022 Key Record Dates |
| Last Update Posted: | March 13, 2023 |
| Last Verified: | March 2023 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Metastatic renal cell carcinoma (mRCC) Objective response Treatment pause Treatment continuation |
|
Carcinoma Carcinoma, Renal Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Kidney Neoplasms Urologic Neoplasms |
Urogenital Neoplasms Neoplasms by Site Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Kidney Diseases Urologic Diseases Male Urogenital Diseases |